
Conference Coverage
Latest Content

Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure

Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years

Climate Change Will Affect Pulmonary Health Across Intensive Care

The Growing ADC Landscape in TNBC Brings Questions, Opportunities: Rebecca Dent, MD, MSc

Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Experts at ESMO Congress highlighted the urgent need for open discussions on sexual health post cancer treatment, emphasizing its impact on quality of life.

Combination therapy with enfortumab vedotin and pembrolizumab significantly reduces progression and mortality risk of muscle invasive bladder cancer in first-line treatment.

The Hearing Loss Association of America advocates for early hearing loss detection, addressing mental health, and improving accessibility to enhance quality of life.

Adjuvant abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy prolonged survival in high-risk HR-positive, HER2-negative early-stage breast cancer.

Researchers identify FGFR4, FLT1, and WNT5A as key biomarkers and suggest dovitinib and nintedanib as new targeted therapies for colorectal cancer.

Patients successfully self-administer rozanolixizumab for generalized myasthenia gravis (gmG), preferring manual push delivery over infusion pumps in a phase 3 trial.

Metallomic correlations suggest environmental and metabolic metals act together to accelerate renal damage.

Integrated data suggest higher tryptophan activity is associated with reduced inflammation and improved outcomes in RA.

Lesion-based disconnectome mapping suggests that the pattern, not the quantity, of brain damage determines cognitive outcomes in patients with MS.

Education on birth control and its potential adverse effects is vital to women choosing the type that best suits them.